Introduction
Gene ampli®cation is one of the most common forms of genetic abnormality occurring in human breast cancer that is manifested cytogenetically in the form of abnormal chromosomal segments in tumor cells (Devilee et al., 1994) . Genes frequently reported to be ampli®ed in breast cancer include c-erbB2, c-myc, cyclin D1 that are harbored on chromosomal segments 17q21, 8q24 and 11q13 respectively. Availability of the cloned probes for the ampli®ed genes ®rst helped detection of this genetic abnormality. Recent application of molecular cytogenetic techniques of chromosome microdissection and comparative genomic hybridization (CGH) have identi®ed additional chromosomal sites of DNA ampli®cation in human breast cancer cells (Guan et al., 1994; .
Among the novel sites of ampli®cation identi®ed, chromosomal region 20q11-q13 was detected in about 12 ± 18% of primary breast tumors and 40% of breast tumor cell lines. CGH analysis also revealed strong association between ampli®cation of DNA around chromosome 20q13 region and poor prognosis in node negative breast cancer (Isola et al., 1995) . These data suggest that chromosome segment 20q11-q13 harbors one or more novel oncogene(s), whose overexpression due to ampli®cation plays a critical role in progression of breast cancer. Attempts are therefore underway to map the common region of ampli®cation spanning this chromosome segment in breast cancer cells and clone the ampli®ed, overexpressed gene(s) harbored on this amplicon.
Interphase FISH analysis with anonymous cosmid probes and gene speci®c P1 clones earlier was reported to de®ne approximately 1.5 Mb of minimum common region of ampli®cation at chromosome 20q13.2 in breast tumor cells that excluded all candidate genes in the region from this amplicon . More recent FISH analysis with additional region speci®c cloned probes have however revealed that the ampli®cation pattern of 20q chromosomal DNA in breast cancer cells is more complex and extends over a longer distance than previously reported (Tanner et al., 1996; Sen et al., unpublished results) .
We have generated a YAC based physical map of the ampli®ed region. These YACs are being used to identify expressed transcripts encoded on the ampli®ed chromosome segment by the approach of direct cDNA selection. Direct cDNA selection has proved to be an eective method for isolating genes from several large genomic regions (Lovett et al., 1991; Morgan, 1992; Osborne-Lawrence et al., 1995) . This methodology involves isolation of expressed sequences through the hybridization of a library or pool of cDNAs to a genomic target. In this paper we describe isolation, by direct selection, of a partial cDNA sequence for a putative serine/threnonine kinase encoding gene harbored on chromosome 20q13 that is ampli®ed and overexpressed in human breast cancer cell lines. This novel gene being called BTAK (Breast Tumor Ampli®ed Kinase) shares signi®cant homology with the kinase domains of yeast and Drosophila kinase known to be involved in chromosome segregation (Francisco et al., 1994; Glover et al., 1995) . BTAK gene maps close to the region on 20q amplicon that has been associated with aggressive breast cancer.
Results
To assess BTAK gene copy number in breast cancer cells, genomic DNAs from three tumor cell lines BT474, MCF7, SKBR3 and two control cell lines WI38, MCF10 were digested with restriction enzymes, electrophoresed through agarose gel and then Southern blot hybridized with BTAK cDNA probe. As shown in Figure 1a , all the three breast tumor cell lines revealed ampli®ed signal intensities on genomic EcoRI fragments of about 8.0 kb and 5.5 kb sizes. Quantitation of ampli®cation level was done by comparing the ratio of signal intensities between ampli®ed BTAK hybridizing bands and a b actin hybridizing band among the tumor cell line and control cell line DNAs. This analysis revealed that BTAK gene is about 36, 56, and 86 ampli®ed in the breast tumor cells SKBR3, MCF7 and BT474 respectively.
The BTAK probe besides detecting ampli®ed genomic fragments also consistently hybridized with an unampli®ed genomic fragment of about 6.1 kb size in all of the ®ve cell line DNAs. This result indicated to us that BTAK probe cross hybridized to a member of a related sequence family that is not ampli®ed in the tumor cells.
Steady state level of BTAK transcript was analysed in the same three breast tumor cell lines and the two control cell lines by Northern blot hybridization of their mRNA with BTAK cDNA probe. Distinct hybridization signal on mRNA of about 2.4 kb size was detected in all the cell types. There was no other heterogeneity in the transcript size revealed in these cells. Level of expression of the transcript was markedly higher in the breast tumor cell lines compared to the control cell lines. Among the cell lines, BTAK mRNA levels correlated with the extent of ampli®cation of the gene detected in each case. Thus BT474 with highest gene copy number was found to express at the highest level while MCF7 and SKBR3 cells with progressively lower degree of ampli®cation of the gene expressed the transcript at an intermediate and lowest level among the three cell lines (Figure 1b) . Level of BTAK mRNA over expression was quantitated in the tumor cell lines by measuring the signal intensity of the BTAK mRNA band and normalizing the values for mRNA loading according to the b actin mRNA hybridization signal detected in each lane (Figure 1c ). This analysis revealed that compared to the control cell lines, BTAK mRNA is expresssed at about threefold, sixfold and 10-fold excess in SKBR3, MCF7 and BT474 cells respectively.
BTAK gene was mapped to chromosome 20q by selective PCR ampli®cation of a BTAK speci®c genomic fragment with DNA from human/rodent somatic cell hybrid cells containing either an intact or portion of human chromosome 20. Primers for PCR localization of BTAK were designed from a 260 bp repeat free region of the cloned BTAK speci®c 5.5 kb genomic fragment that showed sequence identity with the cDNA clone isolated.
As shown in Figure 2 , of all the human/rodent hybrid cell DNAs, only the one containing chromosome 20 showed the expected 260 bp PCR product, thus demonstrating that this gene is localized on human chromosome 20. The lane with total human DNA also revealed the BTAK gene speci®c DNA fragment as expected. Ampli®cation of this fragment in two additional hybrid cell DNAs containing fragments of chromosome 20 (CF21-2, CF80-8) helped to further narrow down the site of localization of BTAK gene to chromosome region 20q13. High resolution mapping of the gene was done by PCR screening of the YAC clones utilized for cDNA selection. Clone 757e8 was found positive for the 260 bp BTAK speci®c product. 757e8 is positive for the markers D20S100 and D20S102 which also¯ank the previously described critical region of ampli®cation at 20q13.2 in breast cancer cells (Tanners et al., 1994) . Sequencing of the two complementary strands of the insert in the cDNA clone pcBTAK7 revealed that it contained 660 bp. Complete sequence of the cloned cDNA is shown in Figure 3 . An open reading frame was identi®ed which agreed with the highest scoring known coding sequences. Predicted amino acid sequence of the translated peptide corresponding to the open reading frame is shown with single letter amino acid symbols below the nucleotide sequence in the ®gure. The BTAK peptide sequence was analysed for similarity with known peptides available in the Gene Pept database. The four highest scoring sequences included two unpublished kinases p46x1Eg22 and p46Eg265 from Xenopus laevis, aurora protein kinase from Drosophila and Ip11 protein kinase from S cerevisae all belonging to serine/ threonine family of kinases (Figure 4) . BTAK revealed about 70% identity with the X laevis kinases and about 50% identity with the aurora and Ip11 kinases. One peptide from X laevis and the ones from Drosophila and S cerevisae were aligned with the deduced sequence from pcBTAK7 using PILE UP and the ends terminated to match all the four sequences. Conserved amino acid residues for the kinase domain primary structure are also shown in the alignment as the consensus line in Figure 4 . First 10 of the 12 subdomains recognized in the kinase domains could be assigned on the deduced amino acid sequence of the pcBTAK7. It is likely that the remaining subdomains will be identi®ed when the full length sequence is isolated. Nine kinase domain residues recognized as invariant or nearly invariant throughout the kinase superfamily (Hanks and Hunter, 1995) were also found conserved in the deduced BTAK peptide.
Discussion
We have isolated a novel human gene named BTAK localized on chromosome 20q13 that is ampli®ed and overexpressed in breast cancer cell lines.
Recent FISH studies of breast tumor cells with P1 and cosmid probes de®ning genes and loci along 20q have demonstrated that in addition to the previously described critical region of ampli®cation on 20q13 , two other non syntenic regions, 3 Mb and 20 Mb proximal spanning the segments 20q11 and 20q12 are also ampli®ed in breast tumor cells (Tanner et al., 1996) . These results are in agreement with those obtained by our group also. Among the expressed sequences localized on these regions, vitamins D hydroxylase (CYP24) gene and a cellular apoptosis susceptibility (CAS) gene (Brinkman et al., 1996) on 20q13, as well as the PTP1B/PTPN1 gene encoding a nonreceptor tyrosine phosphatase on 20q12 overexpressed in breast carcinomas (Wiener et al., 1994) have been implicated as critical candidate genes on these amplicons. Recently, however, low level ampli®cation of CAS gene in only selected cell lines and primary tumors has been cited as an evidence against this gene being the target for 20q ampli®cation. Similarly, due to lack of correlation between amplification, and overexpression for the remaining genes on 20q amplicon, these have also been excluded as ampli®ed targets in breast tumor cells (Tanners et al., 1996) . Two recently isolated expressed sequences A1B3 Figure 3 Nucleotide sequence of the pcBTAK7 cDNA clone and the predicted amino acid sequence of the peptide corresponding to the open reading frame. Bar on nucleotides 476-652 show the sequence identi®ed in the genomic clone isolated Figure 4 Alignment of deduced BTAK7 peptide with homologous 466leg22, aurora and Ipl1 peptides available in Gen Pept data base using PILEUP. Conserved protein kinase speci®c subdomains are indicated by Roman numerals. Kinase domain speci®c invariant or nearly invariant residues conserved throughout the superfamily are shown in bold. The asterisks denote the protein serine/threonine motifs from the ProSite Dictionary of Bairoch and A1B4 on chromosome 20q are yet to be proven de®nitive targets on the respective amplicon. . BTAK gene, being described in this paper maps close to the critical region of ampli®cation de®ned on 20q13 and shows good correlation between ampli®cation and overexpression in all the three breast tumor cell lines analysed. Further, level of amplification detected on Southern blots in the three cell lines corraborated earlier ®ndings reported in the same cells for genomic probes spanning the critical region based on quantitation of¯uorescence in situ hybridization (FISH) signals or interphase nuclei . The BTAK gene therefore appears to be a strong candidate for being the target on the 20q13 amplicon. FISH studies done in our laboratory with appropriate genomic probes on primary tumor cells support this possibility. Ampli®cation of chromosome 20q DNA has been detected in colon and bladder cancer cells by CGH technique . 20q ampli®cation has also been reported to accompany human papilloma virus 16/E7 mediated transformation of human uroepithelial cells which undergo immortalization and polyploidization at early passages (Rezniko et al., 1994) . In addition to these molecular cytogenetic data, elevated copy number of chromosome 20 has been implicated in several cancer cell types based on their karyotypic analyses. These include lung cancer, gliomas, melanoma, ovarian cancer and neuroblastoma (Mitelman, 1991; Hay et al., 1992) . It would be of interest to ®nd out how many of these malignant cell types contain the ampli®ed and overexpressed BTAK gene.
Sequence analyses of the partial cDNA clone isolated revealed that the BTAK gene encodes a putative member of protein serine/threonine kinase family. Predicted peptide showed conservation of the consensus serine/threonine kinase signature sequences and all the expected subdomain speci®c residues that are implicated as playing essential roles in enzyme function of this family of proteins. This partial BTAK peptide sequence also revealed high degree of homology to previously cloned members of the serine/threonine kinase family. Two members of this protein family called Ipl1 from S cerevisae and aurora from Drosophila have been shown to be involved in the regulation of high ®delity chromosome segregation process. Temperature sensitive conditional S cerevisae IplI mutants missegregate chromosomes at restrictive temperature (Chan and Botstein, 1993) . Mutations in the gene aurora in Drosophila have been reported to give rise to chromosome segregation abnormalities ranging from generation of polyploid nuclei to mitotic arrest depending on the allelic variants of the locus involved (Glover et al., 1995) . Signi®cant sequence homology shared by Ipl1, aurora and BTAK suggests that these proteins belong to a family of conserved protein serine/threonine kinases which are involved in regulation of chromosome segregation process. Phosphorylation and dephosphorylation of serine and threonine residues of proteins are known to be involved in the control of diverse cellular processes including chromosome segregation (Edelman et al., 1987; Cohen, 1989) . The phosphorylation state of a given protein depends on the relative activities of the protein kinase(s) and phosphatase(s) that recognize it as a substrate. It would therefore be important to identify the physiological substrate for the overexpressed BTAK kinase in breast cancer cells to determine how that is involved in the oncogenic transformation process.
Materials and methods

Cell lines, DNAs
Human breast cancer cell lines BT474, MCF7, SKBR3, human breast epithelial cell line MCF10 and diploid human lung ®broblast cell line WI 38 were all obtained from the American Type Culture Collection. Rodent/Human somatic cell hybrid panel containing speci®c human chromosomes were purchased from Corriell Mutant Cell Repository cDNA direct selection YAC DNAs utilized for direct selection were 761c3, 757e8, 886f11, 845f3 and 847g7 spanning the 20qdis. amplicon mapped in BT474 cells (Sen et al., manuscript in preparation) . cDNA selection was performed according to the published method (Lovett, 1994) with some modi®cations.
YAC DNA preparation
To isolate YAC insert DNAs, agarose embedded yeast plugs were subject to pulsed ®eld gel electrophoresis in a TAFE gel apparatus (Beckman Instruments). Recombinant YAC with human DNA insert was identi®ed by Southern blot hybridization of the YAC DNAs with 32 P-labeled total human DNA. Insert containing YAC DNA was puri®ed from another gel run under identical conditions. Gel puri®ed YAC DNA was digested with Sau3A I restriction enzyme and ligated to a linker adapter sequence. The linker adapter sequence consisted of one 22 mer`L' sequence 5'-GATCCCATGGTCGACTCGAGTC-3' and a complementary 18 mer`S' sequence in opposite orientation, 5'-GACTCGAGTCGACCATGG-3' with Sau3A I compatible 5' cohesive termini at the end. Linker adapter ligated YAC DNAs were ampli®ed by PCR in presence of the`S' primer for 30 cycles with each cycle consisting of 948C denaturation for 1 min, 508C annealing for 1 min and 728C extension for 2 min.
cDNA synthesis A cDNA library with mRNA from BT474 cells was made in lgt11 vector utilizing the Superscript Choice System for cDNA synthesis (Gibco BRL) according to the manufacturer's manual. First strand cDNA synthesis was primed using a combination of oligo(dT) and random hexamer sequence in the presence of modi®ed Moloney Murine Leukemia virus reverse transcriptase provided in the kit. cDNA inserts from the library were ampli®ed by PCR in presence of the lgt11 cDNA insert screening amplimers (Clonetech). PCR was carried out for 30 cycles with each cycle consisting of a 948C denaturation step for 45 s, 608C annealing step for 45 s, and a 728C extension step for 2 min.
For selection of cDNAs, 2 mg of denatured YAC DNAs were applied onto nylon membranes using a slot blot apparatus (S&S Minifold II). Membrane was prehybridized with 50 mg of Cot 1 DNA in 1 ml hybridization buer (56SSC, 0.05 M sodium phosphate, 56Denhardt's, 1% SDS, 100 mg denatured sheared salmon sperm DNA) at 658C for 4 h. At the same time to preblock repeat and nonspeci®c hybridization of cDNA sequences, 2 mg of PCR ampli®ed BT474 cDNA was prehybridized with 2 mg of Cot 1 DNA, 100 ng of ribosomal DNA, 10 ng of rYAC 4 vector DNA, 100 ng of yeast DNA in 200 ml of hybridization buer at 658C for 4 h. The DNA mix was then added to the membranes with YAC DNA and hybridization allowed to go for overnight. Membranes were then washed with 26SSC, 0.1% SDS at room temperature followed by 0.16SSS, 0.1% SDS at 658C. cDNA hybridizing with the target YAC insert DNA was then eluted by incubating the membranes in 100 ml of boiling water for 10 min. Primary selected cDNA inserts were ampli®ed with PCR and the selection procedure was repeated one more time. Secondary, selected cDNA ampli®ed by PCR was cleaved with EcoRI and ligated to EcoRI digested lgt11 vector arms, packaged in vitro and plated.
Recombinant plaques were plated at a density of about 200 per 150 mm plate and transferred to Hybond N transfer membranes (Amersham). Filters were hybridized with radiolabeled total human DNA to eliminate the transcripts from intermediate repeats and from other highly expressed sequences such as ribosomal genes. Phages that failed to hybridize were isolated and analysed as described below.
Inserts from individual clones were obtained by PCR ampli®cation. Inserts were pooled into groups of four and each pool was used as one probe on Northern blots containing RNA from control breast epithelial cell line MCF10 and breast tumor cell line BT474. It was rationalized that if one ampli®ed gene encoded transcript in the pool expressed at a level four times or higher in BT474 cells than its single copy homologue in MCF10 cells, signal intensity for the ampli®ed gene encoded transcript in BT474 RNA lane would appear equal or stronger than that detected in MCF10 RNA lanes. Among the ®rst nine pools (36 independent clones) isolated and screened in this manner, one pool led to isolation of the cDNA clone being described in this paper. Hybridization analyses of the four probes from this pool, separately on four dierent Northern blots, identi®ed one clone with an insert size of about 0.7 kb that detected a distinctly overexpressed transcript of about 2.4 kb in the BT474 cells.
Southern and Northern blot analysis
Southern and Northern blot hybridization analyses of DNA and RNA were performed according to standard protocols (Sambrook et al., 1989) as described by us earlier (Sen et al., 1994) . Probes were labeled with [a 32 P]dCTP by random priming utilizing the random primed DNA labeling kit (Boehringer Mannheim).
Isolation of 5.5 kb BTAK genomic clone
Since Southern blot hybridization of EcoRI digested breast tumor cell DNAs with BTAK cDNA probe revealed an unampli®ed fragment in addition to the ampli®ed ones, we decided to isolate the ampli®ed BTAK speci®c genomic sequences from a size fractionated BT474 genomic DNA sublibrary. In order to isolate the BTAK speci®c ampli®ed 5.5 kb EcoRI fragment, a genomic sublibrary of EcoRI digested 5 ± 6 kb DNA was made in lgt11 vector following puri®cation of the gel fractionated DNA with Gene CAPSULE (Midwest Scienti®c). 1610 5 p.f.u. were screened with radiolabelled BTAK cDNA probe. Clone containing 5.5 kb BTAK genomic sequence was isolated. Restriction enzyme digestion and Southern blot hybridization of the genomic clone with the cDNA probe identi®ed a 1.0 kb EcoRI ± SmaI fragment sharing sequence identity between the two. This 1.0 kb EcoRI ± SmaI fragment was subcloned in pBlue Script (pBS) and sequenced.
DNA sequencing and computational analyses DNA sequencing was done by the Dideoxy chain termination method using the Seqnanase Version 2.0 DNA sequencing kit (United Stated Biochemical) manually in the laboratory and also on an Applied Biosystems Model 373A Automated DNA sequencer available as a core sequencing facility in our institution.
Computer analyses of the sequence was done using the Genetics Computer Group Package (Madison, WI). The GenBank database (Release 96.0) was searched using the BLAST software package (Altschull et al., 1990) . A second search was made over the GenPept database to identify known peptide sequences. As an additional approach BTAK peptide was analysed with the MOTIFS program to identify de®ned motifs.
